Company Analysis West Pharmaceutical Services, Inc.
1. Summary
Advantages
- Current debt level 5.86% is below 100% and has decreased over 5 years from 14.07%.
- The company's current efficiency (ROE=20.6%) is higher than the sector average (ROE=-80.86%)
Disadvantages
- Price (219.4 $) is higher than fair price (108.9 $)
- Dividends (0.242%) are below the sector average (1.32%).
- The stock's return over the last year (-38.76%) is lower than the sector average (-20.98%).
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| West Pharmaceutical Services, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 8.4% | -13.7% | -3.1% |
| 90 days | -32.1% | -21.8% | -0.7% |
| 1 year | -38.8% | -21% | 17.6% |
WST vs Sector: West Pharmaceutical Services, Inc. has significantly underperformed the "Healthcare" sector by -17.79% over the past year.
WST vs Market: West Pharmaceutical Services, Inc. has significantly underperformed the market by -56.37% over the past year.
Stable price: WST is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: WST with weekly volatility of -0.7455% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (219.4 $) is higher than the fair price (108.9 $).
Price is higher than fair: The current price (219.4 $) is 50.4% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (45.04) is lower than that of the sector as a whole (114.5).
P/E vs Market: The company's P/E (45.04) is lower than that of the market as a whole (70.26).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (9.28) is lower than that of the sector as a whole (9.44).
P/BV vs Market: The company's P/BV (9.28) is lower than that of the market as a whole (22.61).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (9.06) is higher than that of the sector as a whole (4.13).
P/S vs Market: The company's P/S indicator (9.06) is lower than that of the market as a whole (15.24).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (29.9) is higher than that of the sector as a whole (17.79).
EV/Ebitda vs Market: The company's EV/Ebitda (29.9) is higher than that of the market as a whole (24.37).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 14.28% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (14.28%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-57.12%).
5.4. ROE
ROE vs Sector: The company's ROE (20.6%) is higher than that of the sector as a whole (-80.86%).
ROE vs Market: The company's ROE (20.6%) is higher than that of the market as a whole (18.07%).
5.5. ROA
ROA vs Sector: The company's ROA (15.5%) is higher than that of the sector as a whole (6.71%).
ROA vs Market: The company's ROA (15.5%) is higher than that of the market as a whole (6.49%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (28.73%) is higher than that of the sector as a whole (15.68%).
ROIC vs Market: The company's ROIC (28.73%) is higher than that of the market as a whole (9.31%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0.242% is below the average for the sector '1.32%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 0.242% has been steadily paid over the past 7 years, DSI=0.93.
Weak dividend growth: The company's dividend yield 0.242% has been growing weakly or stagnant over the past 5 years. Growth over only 2 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (9.61%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 18.02.2025 | Green Eric Mark President, CEO and Board Chair |
Purchase | 211 | 519 271 | 2 461 |
| 18.02.2025 | Witherspoon Charles VP & Treasurer |
Purchase | 211 | 13 926 | 66 |
| 18.02.2025 | Winters Chad VP, Chief Accounting Officer |
Purchase | 211 | 17 302 | 82 |
| 18.02.2025 | Favorite Annette F Sr. VP & Chief HR Officer |
Purchase | 211 | 51 906 | 246 |
| 07.05.2024 | Green Eric Mark President, CEO and Board Chair |
Sale | 366.65 | 24 198 900 | 66 000 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
